Tab. I.
Basic patient characteristics
| Factors | Group A (without MACEs) | Group B (with MACEs) | p |
|---|---|---|---|
| n = 117 | n = 85 | ||
| Age [years] | 50.0 42.0/54.0 | 47.0 40.0/54.0 | NS |
| Men [%] | 100 (85.5%) | 67 (78.8%) | NS |
| HF duration [months] | 12.0 6.0/36.0 | 24.0 7.0/60.0 | < 0.05 |
| NYHA II | 99 (84.6%) | 65 (76.5%) | NS |
| 6-minute walk test [m] | 401.4 ± 52.6 | 330.5 ± 69.9 | < 0.001 |
| LVEF [%] | 30.0 25.0/34.0 | 20.0 24.0/34.0 | NS |
| LVEDV [mm] | 204.1 ± 71.8 | 222.9 ± 81.2 | 0.0656 |
| RVEDD [mm] | 26.0 ± 6.0 | 29.8 ± 7.5 | < 0.001 |
| E/A | 1.41 0.46/1.71 | 1.74 1.21/3.61 | < 0.001 |
| eGFR < 90 [ml/min/1.73 m2] | 59 (51.7%) | 51 (60.7%) | NS |
| hsCRP [mg/l] | 1.70 1.03/3.22 | 2.73 1.20/5.61 | < 0.05 |
| NT-proBNP [pg/ml] | 620.1 296.1/1218.1 | 1701.0 301.1/3757.0 | < 0.001 |
| Alkaline phosphatase [U/l] | 62.0 52.0/72.0 | 74.0 57.0/90.0 | < 0.01 |
| Bilirubin [mmol/l] | 18.5 ± 9.3 | 22.2 ± 12.1 | < 0.05 |
E/A – E/A ratio, eGFR – estimated glomerular filtration rate, HF – heart failure, hsCRP – high sensitivity C-reactive protein, LVEDV – left ventricular end diastolic volume, LVEF – left ventricular ejection fraction, MACEs – major adverse cardiovascular events, NT-proBNP – N-terminal pro-B-type natriuretic peptide, NYHA – New York Heart Association, RVEDD – right ventricular end diastolic diameter